Navigation Links
Transcept Pharmaceuticals Appoints Key Senior Executives
Date:7/2/2008

cutives with extensive experience in both pharmaceutical development and commercialization," said Ms. Koppy. "I look forward to leading the Transcept effort to build partner relationships and to license development programs."

About Intermezzo(R)

Transcept Pharmaceuticals' lead product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge) employs the company's proprietary Bimucoral(R) technology in a mint-flavored, sublingual lozenge formulated to dissolve under the tongue in approximately two minutes. This novel pH modification delivery system has been shown to accelerate the bioavailability of zolpidem, despite the substantially lower Intermezzo(R) dose vs. the doses employed with previously available forms of this active agent.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to submit an NDA in the third quarter of 2008. Transcept is also developing TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. For further information, please visit the Company's website at: http://www.transcept.com.

Contacts:

Transcept Pharmaceuticals, Inc. The Ruth Group

Michael Gill Investors / Media

Director of Communications Stephanie Carrington
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed unknowingly ... this time period, doctors did not know that they needed ... death of vulnerable patients. In the same way, medical interns ... unwittingly transmitting herpes viruses to their patients. The CBCD explains. ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... A key lawmaker who often disagrees with Governor Jim ... saw nothing inappropriate about the governor's use of an executive ... cell companies. , ,Meanwhile, the executive order, signed Tuesday at ... the director of Pro Life Wisconsin. , ,Ted Kanavas, R-Brookfield, ...
... GE Healthcare has received federal approval for yet ... for the estimated 20% of Americans that are considered obese. ... the Food and Drug Administration for its new wide bore ... The system is designed to meet growing demand for better ...
... Is your brand valuation worth a billion dollars today? Maybe yes ... At the end of the day, all the work you have ... and services in your marketplace adds up in an abstract space ... equity can be measured as a real, soft asset. It can ...
Cached Biology Technology:Republican sees nothing wrong with Doyle's use of executive order 2FDA okays new GE tomography system 2Is your brand worth billions? 2Is your brand worth billions? 3
(Date:7/9/2014)... from China challenges the commonly held belief that birds ... to fly. The birdlike fossil is actually not a ... of a tiny tree-climbing animal that could glide, say ... Blanding, Utah, and Alan Feduccia of the University of ... of Ornithology . , The fossil of the ...
(Date:7/9/2014)... measurement results accrue. To completely and systematically archive ... In fact, researchers in the life sciences spend ... to an online survey of 70 people working ... for Applied Information Technology FIT in Sankt Augustin. ... no centralized or structured approach to data collection ...
(Date:7/9/2014)... with high levels of vitamin D in their blood are ... , Patients with the highest levels of vitamin D have ... lowest levels, the findings reveal. , The study is the ... bowel cancer patients after their diagnosis which includes that ... sources with their long term survival prospects. , ...
Breaking Biology News(10 mins):Researchers declassify dinosaurs as being the great-great-grandparents of birds 2Managing the data jungle 2Managing the data jungle 3
... to stop the spread of drug resistance in typhoid fever, ... published in the journal eLife . The ... bacteria can out-compete drug sensitive strains when grown in the ... is transmitted by consuming food or drink that is contaminated ...
... 9, 2013 /PRNewswire-iReach/ -- With the holiday season comes the ... American will put on up to five pounds in just ... CDC (Center for Disease Control) more than 65% of Americans ... obese. (Photo: http://photos.prnewswire.com/prnh/20131209/MN29878 ) ...
... inhibitors (SSRIs) are the most commonly prescribed antidepressants, but ... often try several different SSRI medications, each with a ... is effective. It takes three to four weeks to ... and their families continue to suffer. Now researchers ...
Cached Biology News:Antibiotic-resistant typhoid likely to spread despite drug control program 2HCG Injections and B12 shots now in stock at US Vitamin Injections Site 2A personal antidepressant for every genome 2A personal antidepressant for every genome 3
MAb to Desmoplakin I & II Desmoplakin I & II...
... in conjuction with Annexin V-FITC to distinguish ... of apoptosis (Annexin V positive, PI negative) ... of apoptosis or already dead (Annexin V-FITC ... the orange range of the spectrum using ...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... Sf9 Insect Cells are derived from the Spodoptera ... optimal growth, use in transfections, plaque assays, virus ... in a protocol that optimizes recovery of viable ... in serum-free BacVector Insect Cell Medium and can ...
Biology Products: